Dizal Pharma is a biopharmaceutical company dedicated to the discovery, development, and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases worldwide. Deep-rooted in translational science and molecular design, it has established an internationally competitive portfolio of six assets with two in global pivotal studies.

Founded in 2017, Dizal was established as a joint venture that incorporated AstraZeneca’s Innovation Center China capabilities and launched with rights to develop multiple pipeline programs while initiating new clinical development efforts.